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6-Hydroxydopamine (6-OHDA) is a neurotoxic compound commonly used to induce
dopamine (DA) depletion in the nigrostriatal system, mimicking Parkinson’s disease
(PD) in animals. The aim of the present study was to evaluate the 7-day effect of uni-
lateral nigral lesion on rat brain monoamine neurochemistry. Five brain regions were
examined: the brain stem, cerebellum, hippocampus, striatum, and cortex. 6-OHDA-
unilateral lesion dramatically modified DA, serotonin (5-HT) and their metabolites con-
tents in both sides of the different brain nuclei. Furthermore, unilateral 6-OHDA lesion
reduced DA and 5-HT contents and produced a robust inversion of their turnover in the
nonlesioned side compared to sham-operated rats. These data suggest that 6-OHDA
unilateral nigral lesion produces bilateral monoamine level modifications, and this
piece of evidence should be taken into account when one interprets data from animal
models of unilateral PD.
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Introduction
Parkinson’s disease (PD) is the second most
common neurodegenerative disease, character-
ized by the loss of 50–70% of dopaminergic
(DAergic) neurons located in the substantia ni-
gra pars compacta (SNc), with a concomitant
reduction of striatal DA levels.1–6 Current evi-
dence suggests an involvement of both environ-
mental and genetic factors in the progression
of PD. Important factors include: formation of
free radicals, impaired mitochondrial activity,
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increased sensitivity to apoptosis, excitoxicity,
and inflammation.3,7–10 Nevertheless, the spe-
cific etiology of PD is still unknown. Research
on the pathogenesis of PD has rapidly advanced
due to the development of animal models that
have been shown to be not only essential for bet-
ter understanding of the pathogenesis and pro-
gression of PD but of paramount importance
for testing therapeutic agents for the treatment
of PD patients.2,8,9,11–17
Several toxin-induced animal models sim-
ulate motor deficits occurring in PD. The
most frequently used toxins in PD mod-
els are the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP),13 or 6-
hydroxydopamine (6-OHDA).11,14,18 Although
MPTP is a valuable model of PD especially in
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nonhuman primates, its use has some caveats.
Indeed, MPTP injection causes a bilateral
Parkinson syndrome and, more importantly, a
spontaneous recovery of Parkinsonian symp-
toms might occur.19,20
On the other hand, the 6-OHDA PD-model
leads to stable motor deficits over time due to a
permanent degeneration of virtually all DAer-
gic neurons in the SNc after intracerebral in-
jection of 6-OHDA into the rat nigrostriatal
pathway.21
6-OHDA is a hydroxylated analogue of the
natural neurotransmitter DA.18 and selectively
destroys catecholaminergic neurons.22 Inside
neurons, 6-OHDA accumulates in the cytosol
and induces cell death and exhibits hallmarks of
apoptosis.23 As far as mechanisms underlying
toxicity of 6-OHDA are concerned, participa-
tion of oxidative stress leading to excessive gen-
eration of free radicals and cell death is firmly
established.21 The degeneration of dopaminer-
gic neurons in the SNc and the resulting loss
of their nerve terminals in the striatum are re-
sponsible for most of the motor disturbances
seen in PD.
In the present study we injected the 6-
OHDA unilaterally into the SNc to achieve
directly DAergic cell loss. We performed
quantitative postmortem investigations of 6-
OHDA effect, measuring tissue levels of brain
monoamines and their metabolites such as DA,
serotonin (5-HT), dihydroxyphenylacetic acid
(DOPAC), homovanilic acid (HVA), and 5-
hydroxyindoleacetic acid (5-HIAA) by means
of high performance liquid chromatography
(HPLC). The areas of investigation were: cere-
bellum, brain stem, striatum, hippocampus,
and cerebral cortex. Monoamine levels were
dramatically modified by 6-OHDA lesion not
only in the ipsilateral side but, strikingly, in
the contralateral side compared to the values
of sham-operated rats. These findings are dis-
cussed in terms of the current state of knowl-
edge of PD pathophysiology and we suggest
that they should be taken into account when
one interprets data from animal models of uni-
lateral PD.
Materials and Methods
Male Sprague−Dawley rats from Charles
River Laboratories (Calco, Varese, Italy) were
housed at appropriate environmental condi-
tions (21 ± 2◦C room temperature, 12-h
light/dark cycle, 40–60% humidity). Water and
food was provided ad libitum. Procedures in-
volving animals and their care were conducted
in accordance with the institutional guidelines
that are in compliance with national (D.L. n.
116, G.U., suppl. 40, 18 Febbraio 1992) and
international laws and policies (EEC Council
Directive 86/609, OJ L 358,1, Dec. 12, 1987;
NIH Guide for the Care and Use of Laboratory
Animals, NIH Publication N. 85-23, 1985 and
Guidelines for the Use of Animals in Biomed-
ical Research, Thromb. Haemost. 58, 1078–
1084, 1987).
Rats were anesthetized with chloral hydrate
(400 mg/kg i.p.) and placed on a stereotaxic in-
strument (David Kopf Instruments, Tujunga,
CA, USA). The 6-OHDA was dissolved in
0.9% saline solution of ascorbic acid (0.05%).
6-OHDA (5 μg, free base) in a volume of 5 μl
was infused into the left SNc (AP = −5.2,
L = 2.0, V = −7.5 from the dura surface
and respect to the bregma).24 Control rats
received only the ascorbic acid solution. A
week after the 6-OHDA lesion, vehicle and
6-OHDA-treated rats were killed by decapi-
tation. Brains were rapidly removed, striata,
hippocampi, brain stems, cortices, and cere-
belli were dissected, frozen on dry ice, and
stored at −80◦C until assay. Tissue samples
were homogenized in 1 ml 0.1 N perchloric acid
and 0.45 μM of 3,4-dihydroxybenzylamine
(DHBA) and afterwards centrifuged for 15 min
at 12,000 rotations/min. An aliquot of the
supernatant was filtered and transferred to
an Eppendorf tube. Levels of 5-HT, 5-HIAA,
DA, DOPAC, and HVA were measured by
reversed-phase HPLC with electrochemical
detection.
The mobile phase was composed of
24 mM citric acid, 16 mM Na2HPO4,
1.22 mM heptanesulphonic acid sodium salt,
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0.19 mM EDTA, and 17.5% methanol, ad-
justed to pH 2.8 with orthophosphoric acid.
This mobile phase was delivered at 1 ml/min
flow rate (Pump 420, Kontron Instruments, Mi-
lano, Italy) through a Supelcosyl LC-8 column
(C8, 4.0 x 250 mm, 5 μm, Supelco, Bellefonte,
PA, USA). Samples were injected manually into
the HPLC, and detection of DA or 3,4-DHBA
was carried out with a coulometric detector
(Coulochem II, ESA, Bedford, MA, USA) cou-
pled to a dual electrode analytic cell (model
5014). The potential of the first electrode was
set at −175 mV and the second at +175 mV.
Under these conditions, the sensitivity for DA
was 0.35 pg/20 μl with a signal to noise ratio
of 3:1.
To ensure maximal reproducibility, 6-
OHDA dissolved in 0.1% ascorbate/saline was
prepared in advance, filtered through 0.22-μm
filters, aliquoted, and stored at −20◦C. Im-
mediately before use aliquots were gently de-
frosted, loaded into a designated microperfu-
sion pump, and protected from light. Control
rats were injected with an equal volume of the
vehicle only.
The concentration of each compound, i.e.,
DA, 5-HT, DOPAC, HVA, and 5-HIAA
was calculated by comparison with the in-
ternal standard (DMBA). Ratios of metabo-
lite level/monoamine level (DOPAC/DA,
HVA/DA, 5-HIAA/5-HT) and indices of
monoamine turnover were also calculated.
Data correspond to Mean ± SEM values of
absolute levels obtained in each experimen-
tal group. 3,4-DHBA content in each sample
was expressed as a percentage of the average
baseline level calculated from three fractions
collected before neurotoxin infusion. Data are
expressed as Mean ± SEM of the contents
obtained in each experimental group. Data
were analyzed by one-way analysis of variance
(ANOVA) with repeated measures, followed by
the Fisher’s protected least significance differ-
ence post hoc test (Fisher’s PLSD) to allow multi-
ple comparisons between groups. All statistical
analyses were performed with StatView version
5.0.1 (SAS Institute Inc., Cary, NC, USA).
TABLE 1. Concentrations‡ in Various Rat Brain Re-





Brain stem 503 ± 32 114 ± 27∗∗ 223 ± 18#
Cerebellum n.d. n.d. n.d.
Striatum 5057 ± 573 381 ± 88∗∗ 3550 ± 482#
Hippocampus n.d. n.d. n.d.
Cortex 670 ± 25 23 ± 6∗∗ 110 ± 37##
5-HT
Brain stem 1917 ± 213 786 ± 106 636 ± 63##
Cerebellum 126 ± 19 278 ± 19∗ 95 ± 26#
Striatum 668 ± 132 149 ± 8 139 ± 39##
Hippocampus 432 ± 78 98 ± 16 80 ± 17##
Cortex 924 ± 83 187 ± 41∗ 394 ± 184##
‡Of dopamine (DA) and serotonin (5-HT) (ng/g of
wet weight of tissue)
Data are Means ± SEM from 10 experiments. For
statistical analyses, one-way ANOVA and the Fisher’s
PLSD post hoc test were used. ∗vs. contralateral side
(6-OHDA DX), #, vs. controls (sham operated); ∗or
#P < 0.05, ∗∗ or ##P < 0.01.
6-hydroxydopamine hydrobromide (6-
OHDA) was from Aldrich Chem. Co.
Milwaukee, WI, USA.
Results
Unilateral lesion dramatically modified DA
and 5-HT and their metabolites levels in
both sides of rat brains (Table 1). DA levels
were reduced by 89.2 ± 9.5% (P < 0.01),
79.3 ± 11.2% (P < 0.01), 48.8 ± 6.5%
(P < 0.01) in the left striatum, cortex, and brain
stem, respectively, compared to the right hemi-
sphere (Table 1). Furthermore, DA levels of the
right side of the lesioned rats were also reduced
by 29.8 ± 6.9% (P < 0.01), 83.6 ± 12.3%
(P < 0.01), 55.7 ± 9.8% (P < 0.01) in the stria-
tum (Fig. 1), cortex, and brain stem, respec-
tively, compared to control (sham-operated)
rats (Table 1). Although the 5-HT levels in
the lesioned rats were similar in both sides,
a very significant reduction in contents and
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Figure 1. Effect of 6-OHDA on concentration of dopamine (DA), 3,4-
dihydroxyphenylacetic acid (DOPAC), homovanilic acid (HVA), serotonin (5-HT), and
5-hydroxyindoleacetic acid (5-HIAA) (ng/g of wet weight of tissue) in striatum of control
animals and rats with 6-OHDA nigral lesion (n = 5, for each group). Data are Means ± SEM.
For statistical analyses one-way ANOVA and the Fisher’s PLSD post hoc test were used. ∗vs.
controlateral side (6-OHDA DX), #vs. controls (sham-operated); ∗P < 0.05, ∗∗ or ##P < 0.01.
an inversion of 5-HT turnover (5-HIAA/5-
HT) compared to control rats was revealed
(Table 1).
Discussion
In the present work we assessed the effect of
6-OHDA on brain areas that receive DAergic
afferent such as the ventral mesenchephalon,
the brain stem, striatum, hippocampus, and
cortical areas. Strikingly, we showed that the
modifications induced by unilateral 6-OHDA
lesion are far from being a simple depletion of
DA contents. Although the degree of depletion
was usually less conspicuous in other brain ar-
eas than in the striatum, all areas were affected
by the lesion.
In agreement with a large body of evi-
dence,12,25,26 we confirmed that moderate27
unilateral 6-OHDA lesion of mesencephalic
SNc neurons caused a massive depletion of
striatal DA contents (up to about 90%) when
measured from the ipsilateral side compared
with the contralateral side of the same an-
imal. Moreover, DA contents were also re-
duced by 50–80% in the left cortex and brain
stem. DAergic metabolites, DOPAC, and HVA
levels showed similar reductions in the brain
stem, striatum, and cortex, like their trans-
mitter. In the striatum and cortex, DOPAC
decline was less expressed than that of DA.
Moreover, the metabolite/neurotransmitter ra-
tio (DOPAC/DA) was increased, and even
inverted in the striatum, compared to the
contralateral side or sham-operated control.
The increased DOPAC/DA ratio probably re-
flects increased DA turnover and DA receptor
sensitization—a compensatory mechanism in
surviving neurons.28 Since this ratio is used as
an index of DA turnover, the alteration of this
ratio in our partially lesioned rats likely reflects
compensatory mechanisms involving altered
DA release, reuptake, or degradation in striatal
neurons.29,30
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Brain stem 67 ± 8 106 ± 19∗ 215 ± 34##
Cerebellum n.d. n.d. n.d.
Striatum 1386 ± 91 390 ± 12∗ 1589 ± 192
Hippocampus n.d. n.d. n.d.
Cortex 136 ± 13 23 ± 4∗ 93 ± 26
HVA
Brain stem 54 ± 14 44 ± 8 38 ± 8
Cerebellum n.d. n.d. n.d.
Striatum 1225 ± 132 907 ± 25∗ 1233 ± 103
Hippocampus n.d. n.d. n.d.
Cortex 96 ± 11.1 56 ± 30 65 ± 13
5-HIAA
Brain stem 622 ± 120 838 ± 65 995 ± 49
Cerebellum 50 ± 7 376 ± 22∗∗ 161 ± 23#
Striatum 307 ± 63 664 ± 121 705 ± 99##
Hippocampus 179 ± 40 470 ± 13 529 ± 15##
Cortex 229 ± 11 376 ± 73 476 ± 13##
DOPAC/DA
Brain stem 0.13 ± 0.02 0.91 ± 0.06 0.96 ± 0.18##
Cerebellum n.d. n.d. n.d.
Striatum 0.27 ± 0.02 1.02 ± 0.13∗∗ 0.45 ± 0.04
Hippocampus n.d. n.d. n.d.
Cortex 0.20 ± 0.05 1.02 ± 0.07∗∗ 0.84 ± 0.07##
5-HIAA/5-HT
Brain stem 0.32 ± 0.05 1.06 ± 0.06∗ 1.56 ± 0.07##
Cerebellum 0.39 ± 0.03 1.35 ± 0.12 1.69 ± 0.08##
Striatum 0.45 ± 0.04 4.44 ± 1.47 5.08 ± 0.25##
Hippocampus 0.40 ± 0.05 4.76 ± 0.82 6.57 ± 0.86##
Cortex 0.24 ± 0.01 2.01 ± 0.18∗∗ 1.20 ± 0.06##
‡Of 3,4-dihydroxyphenylacetic acid (DOPAC), homovanilic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) (ng/g
of wet weight of tissue) and monoamine oxidase activity expressed as metabolite ratios (DOPAC/DA and 5-HIAA/5-
HT).
Data are means ± SEM from 10 experiments. For statistical analyses, one-way ANOVA and the Fisher’s PLSD
post hoc test were used. ∗vs. contralateral side (6-OHDA DX), #vs. controls (sham-operated); ∗ or #P < 0.05, ∗∗ or
##P < 0.01.
In addition, we evaluated the modification
of 5-HT and 5-HIAA induced by 6-OHDA
lesion in our PD model. In fact, it has been
shown that 5-HT plays a role in regulating
the basal ganglia circuitry,31,32 and abnormal-
ities in 5-HT transmission might contribute to
the neural mechanisms underlying PD.31,33,34
Moreover, 5-HT is involved in the movement
abnormalities generally associated with the use
of levodopa (L-DOPA).32,35,36 5-HT tissue lev-
els were unchanged in the brain stem, striatum,
and hippocampus, increased in the cerebellum,
and decreased in the cortex. Its metabolite 5-
HIAA levels were unchanged in all the areas
apart from in the cerebellum, where these levels
increased. 5-HT turnover was also modified; 5-
HIAA/5-HT ratio decreased in the brain stem
and increased in the cortical areas. Contrasting
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results are reported in the literature about the
effect of 6-OHDA lesion on 5-HT brain con-
tents.37–40 It is likely that this variability is due
to the amount of DA lesion achieved in the
different studies.
Taken together, our data show that the spe-
cific pattern of changes in serotonergic activity,
occurring after unilateral 6-OHDA lesion, is
subtle compared to DA modifications.
Unilateral lesions of the nigrostriatal projec-
tion may also have contralateral consequences
when compared to the nonlesioned animal. In
fact, it has been shown that after unilateral
electrolytical and chemical lesions DA content
of the SNc decreases not only ipsilaterally but
contralaterally as well.41 In agreement with this
finding, we revealed a dramatic drop in DA
contents in the right (nonlesioned) side when
compared to the control group. This contralat-
eral decrease was significant in the brain stem,
striatum, and cortex. DOPAC and HVA levels
were instead unchanged. As a consequence, in
the contralateral side we observed a significant
increase in DA turnover. The effect of 6-OHDA
lesion was even more evident in regard to 5-HT
and its metabolite. Indeed, 5-HT brain levels
were decreased and the 5-HIAA/5-HT ratio,
which is an expression of MAO A activity, was
inverted in all the areas of examination. Strik-
ingly, this ratio in the striatum and the hip-
pocampus was greater than 5:1.
Therefore, the loss of DA innervation trig-
gered an increase in DA and 5-HT turnover
in all the brain. Regarding the neurochemistry
of 5-HT, the increase in its turnover and the
concomitant depletion might be the patholog-
ical substrate that predisposes PD patients to
depression. Indeed, besides being a movement
disorder, PD is also associated with numerous
nonmotor symptoms. Mood disturbance, and
especially major depressive disorder, has an
average prevalence of 25–40% in outpatient
settings.42
In summary, the present study provides,
for the first time, compelling evidence that
unilateral intranigral 6-OHDA infusion al-
ters the monoamine neurochemistry of all the
brain. Therefore, although the 6-OHDA model
does not mimic all pathological and clinical
features of human Parkinsonism, it might re-
produce the complex alterations in neurotrans-
mitter chemistry that characterize this neuro-
logical disorder. Our findings therefore suggest
that 6-OHDA unilateral nigral lesion produces
bilateral monoamine level modifications and
this piece of evidence should be taken into
account when interpreting data from animal
models of unilateral PD to avoid errors in the
estimation of lesion effects and, above all, the
activity of neuroprotective substances.
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